Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination with azacitidine, or decitabine, or low-dose ...

11 days ago

Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukaemia

Genentech, a member of the Roche Group, announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of ...

11 days ago

VENCLEXTA® (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML)

VENCLEXTA® (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML)

NORTH CHICAGO, Ill., Oct. 16, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination.

11 days ago

FDA Approves Combination Treatment for Acute Myeloid Leukemia

FDA Approves Combination Treatment for Acute Myeloid Leukemia

Venetoclax in combination with azacitidine was shown to prolong survival and increase chance of remission.

11 days ago

FDA Approves Venetoclax Plus LDAC For Older Patients With Newly Diagnosed AML

FDA Approves Venetoclax Plus LDAC For Older Patients With Newly Diagnosed AML

The FDA granted approval to venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine, a regimen known as LDAC, as treatment of adults patients with aged 75 years or older with newly-diagnosed acute myeloid leukemia or who have ...

11 days ago

FDA Grants Full Approval to Venetoclax Combo in Newly Diagnosed AML

FDA Grants Full Approval to Venetoclax Combo in Newly Diagnosed AML

The FDA has granted regular approval to venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine for patients with newly diagnosed acute myeloid leukemia who are 75 years or older or who have comorbidities precluding intensive ...

11 days ago

FDA Grants Regular Approval to Venclexta Combo for Untreated Acute Myeloid Leukemia

FDA Grants Regular Approval to Venclexta Combo for Untreated Acute Myeloid Leukemia

After granting accelerated approval in 2018, the Food and Drug Administration approved Venclexta in combination with Vidaza, Dacogen or low dose cytarabine in newly diagnosed patients with AML.

11 days ago

Realtime Search Trends

  • Top stories
  • Sports
  • Entertainment
  • Business
  • Sci/Tech